Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday released encouraging long-term results from clinical trials testing UX111, an experimental gene therapy aimed at treating one of childhood's cruelest diseases. The therapy targets Sanfilippo syndrome Type A, a fatal neurodegenerative disorder that steals children's cognitive abilities and motor skills before cutting their lives short.

Understanding the Disease

Sanfilippo syndrome Type A (also called MPS IIIA) happens when mutations in the SGSH gene knock out production of a critical enzyme called heparan N-sulfatase. Without this enzyme, a sugar molecule called heparan sulfate accumulates to toxic levels throughout the brain and body. The result is devastating: rapid cognitive decline, severe behavioral problems, and premature death. It's the kind of disease that makes you appreciate why gene therapy research matters.

What the Data Shows

The new results demonstrate both substantial biomarker improvements and meaningful functional benefits compared with what typically happens to untreated children. Researchers measured cognitive function, communication abilities, and motor skills using the Bayley-III assessment, then stacked those results against natural history data from untreated patients with rapidly progressing forms of the disease.

The numbers tell a compelling story. Children under two years old or with earlier-stage disease when treated showed a 23.2-point improvement (p<0.0001) in mean Bayley-III cognitive raw scores compared to natural history data during the 24-60 month age window. That's not just statistically significant; it represents real functional difference.

Beyond cognition, clinical improvements showed up across the board. Using a separate caregiver-reported measure called Vineland 3, researchers saw comparable gains in communication, motor skills, and personal care abilities. Eight children in the trial reached a 36-month cognitive developmental age, enabling more advanced testing. Here's the kicker: none of the natural-history patients reached this milestone, according to the company's announcement.

Even children who were older or had more advanced disease when treated showed retention of abilities in at least one of three functional areas at their last assessment, exceeding the typical decline pattern seen in untreated kids with the condition.

The Biomarker Story

As of September 2025, the median reduction in cerebrospinal fluid heparan sulfate levels hit 63.98% (p<0.001). This biomarker measures the toxic buildup that drives the neurodegenerative process. Nearly 90% of younger patients and 81.5% of the overall group achieved at least a 50% reduction. The therapy was well-tolerated with a favorable safety profile, which matters enormously when you're talking about treating young children.

What Happens Next

Ultragenyx included this longer-term data in a resubmitted Biologics License Application to the FDA, seeking accelerated approval for UX111. The company expects a review period of up to six months from the resubmission date, with a target decision date landing in the third quarter of 2026.

Price Action: RARE stock was up 0.08% at $24.78 at last check on Tuesday.